|Bid||0.00 x 1200|
|Ask||0.00 x 1200|
|Day's range||185.64 - 189.17|
|52-week range||185.64 - 306.08|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||17.95|
|Earnings date||28 July 2021 - 02 Aug 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||262.90|
Star investor Cathie Wood is usually one to follow. In less than a year, the biotech company ended development of two candidates in one of its rare-disease programs. Now the question is, should you follow Wood's lead and consider shares of this biotech company?
The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.
Shares of the biotech industry leader have taken a big hit thanks to a clinical development pipeline that hasn't produced any big wins lately.